<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Normocalcemic Hypoparathyroidism: Prevalence and Effect on Bone Status in Older Women. The OPUS Study</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">Andrea</forename><surname>Palermo</surname></persName>
							<affiliation key="aff0">
								<orgName type="laboratory">Academic Unit of Bone Metabolism</orgName>
								<orgName type="institution">University of Sheffield</orgName>
								<address>
									<settlement>Sheffield</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="department">Department of Endocrinology and Diabetes</orgName>
								<orgName type="institution">University Campus Bio-Medico</orgName>
								<address>
									<settlement>Rome</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Richard</forename><surname>Jacques</surname></persName>
							<affiliation key="aff2">
								<orgName type="department">School of Health and Related Research</orgName>
								<orgName type="institution">University of Sheffield</orgName>
								<address>
									<settlement>Sheffield</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Fatma</forename><surname>Gossiel</surname></persName>
							<affiliation key="aff0">
								<orgName type="laboratory">Academic Unit of Bone Metabolism</orgName>
								<orgName type="institution">University of Sheffield</orgName>
								<address>
									<settlement>Sheffield</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">David</forename><forename type="middle">M</forename><surname>Reid</surname></persName>
							<affiliation key="aff3">
								<orgName type="department">School of Medicine and Dentistry</orgName>
								<orgName type="institution">University of Aberdeen</orgName>
								<address>
									<settlement>Aberdeen</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Christian</forename><surname>Roux</surname></persName>
							<affiliation key="aff4">
								<orgName type="institution" key="instit1">Cochin Hospital</orgName>
								<orgName type="institution" key="instit2">Paris Descartes University</orgName>
								<address>
									<settlement>Paris</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Dieter</forename><surname>Felsenberg</surname></persName>
							<affiliation key="aff5">
								<orgName type="institution">Zentrum für Muskel-&amp; Knochenforschung</orgName>
								<address>
									<settlement>Charité</settlement>
								</address>
							</affiliation>
							<affiliation key="aff6">
								<orgName type="institution">Universitätsmedizin Berlin</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Claus-C</forename><surname>Glüer</surname></persName>
							<affiliation key="aff7">
								<orgName type="department" key="dep1">Sektion Biomedizinische Bildgebung</orgName>
								<orgName type="department" key="dep2">Klinik für Radiologie und Neuroradiologie</orgName>
								<orgName type="institution">Universitätsklinikum Schleswig-Holstein</orgName>
								<address>
									<settlement>Kiel</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author role="corresp">
							<persName><forename type="first">Richard</forename><surname>Eastell</surname></persName>
							<email>r.eastell@sheffield.ac.uk</email>
							<affiliation key="aff0">
								<orgName type="laboratory">Academic Unit of Bone Metabolism</orgName>
								<orgName type="institution">University of Sheffield</orgName>
								<address>
									<settlement>Sheffield</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>Prof</roleName><forename type="middle">Richard</forename><surname>Eastell</surname></persName>
						</author>
						<author>
							<affiliation key="aff8">
								<orgName type="institution">Academic Unit of Bone Metabolism University of Sheffield</orgName>
								<address>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Normocalcemic Hypoparathyroidism: Prevalence and Effect on Bone Status in Older Women. The OPUS Study</title>
					</analytic>
					<monogr>
						<imprint>
							<date/>
						</imprint>
					</monogr>
					<idno type="MD5">B688083590129EEC158C1F5A1021CE26</idno>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:28+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>PTH</term>
					<term>normocalcemic hypoparathyroidism</term>
					<term>calcium</term>
					<term>bone turnover markers</term>
				</keywords>
			</textClass>
			<abstract/>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Abstract</head><p><s>Objective: There are no consistent data on the prevalence and bone status for normocalcemic hypoparathyroidism (NHYPO) as defined by normal adjusted calcium and low PTH level.</s><s>Our aim is to determine the prevalence and the bone metabolic profile of NHYPO in older women assessing its evolution over the time.</s><s>The second objective is to evaluate the prevalence of the other calcium metabolic disorders.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Design:</head><p><s>The Osteoporosis and Ultrasound Study (OPUS) is a 6-yr prospective study of fracturerelated factors.</s></p><p><s>Participants: a total of 2419 older women (ages 55-79) and 258 younger women (ages <ref type="bibr" target="#b30">[30]</ref><ref type="bibr" target="#b31">[31]</ref><ref type="bibr" target="#b32">[32]</ref><ref type="bibr" target="#b33">[33]</ref><ref type="bibr" target="#b34">[34]</ref><ref type="bibr" target="#b35">[35]</ref><ref type="bibr" target="#b36">[36]</ref><ref type="bibr" target="#b37">[37]</ref><ref type="bibr" target="#b38">[38]</ref><ref type="bibr">[39]</ref><ref type="bibr">[40]</ref> participated.</s><s>Complete follow-up data are available in 1416 subjects.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Measurements A J</head><p><s>the PTH M D different pathological categories using reference intervals from the healthy young women.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results:</head><p><s>We identified 57 subjects with NHYPO (2.4%).</s><s>These women have lower than expected bone turnover as assessed by bone alkaline phosphatase (-14.5%,</s><s>95% CI: -26.2 to -3.0, p=0.007),</s><s>CTX (-66.3%, 95% CI: -74.0 to -56.4,</s><s>p&lt;0.001) and osteocalcin (-36.8%,</s><s>95% CI: -45.6 to -26.6, p&lt;0.001).</s><s>After 6 years, of the 35 NHYPO subjects with follow-up data, none developed overt hypoparathyroidism and only 15 (0.6%) subjects had persistent evidence of NHYPO.</s><s>We also identified 86 subjects (3.6%) affected by hyperparathyroid hypercalcemia.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Conclusion:</head><p><s>This is the first large population-based study that has investigated NHYPO in older women.</s><s>It is fairly common, not always persistent and is characterized by low bone turnover.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Background</head><p><s>Parathyroid hormone (PTH) is the major hormonal mediator of extracellular calcium homeostasis and regulates osteoclastic bone resorption, the renal excretion of calcium and synthesis of 1,25dihydroxyvitamin D. Circulating PTH concentrations display a large inter-individual variability and this variance has been demonstrated to have a strong hereditable component <ref type="bibr" target="#b0">(1)</ref>.</s><s>However, the genetic factors governing serum PTH concentrations remain to be elucidated.</s><s>PTH is an 84 amino-acid peptide, whose secretion by the parathyroid chief cells is regulated by the calcium-sensing receptor (CaSR), which is expressed at the parathyroid cell-surface.</s><s>Mutations of the CaSR gene lead to inherited forms of hypercalcaemia and hypocalcaemia <ref type="bibr" target="#b1">(2)</ref>, and common coding region CaSR single nucleotide polymorphisms (SNPs) have been revealed as determinants of serum calcium concentrations <ref type="bibr" target="#b2">(3)</ref>.</s><s>Cusano and colleagues recently reported the prevalence of normocalcemic hyper (NPHPT) and hypoparathyroidism (NHYPO) in two unselected, non-referral community-dwelling populations identifying a prevalence of 0.4 -3.1% and 1.1 -1.9% respectively (4).</s><s>NPHPT is characterized by normal calcium levels with high PTH in the absence of secondary causes of hyperparathyroidism <ref type="bibr" target="#b4">(5)</ref> and it was officially recognized by the Third International Workshop on the Management of Asymptomatic Primary Hyperparathyroidism <ref type="bibr" target="#b5">(6)</ref>.</s><s>These patients may develop a similar rate of low bone mineral density compared to subjects with primary hyperparathyroidism (PHPT) <ref type="bibr" target="#b6">(7)</ref> and it seems that there is a trend toward a higher recurrence of NPHPT after parathyroidectomy <ref type="bibr" target="#b7">(8)</ref>.</s></p><p><s>While NPHPT is a well-documented diagnostic category, no consistent data are available for NHYPO.</s></p><p><s>The diagnosis of NHYPO has been used for patients who develop hypocalcaemia in response to bisphosphonate therapy having had normal calcium values and low PTH levels prior to starting therapy; such patients were considered to have inadequate parathyroid gland reserve <ref type="bibr" target="#b8">(9)</ref>.</s><s>We cannot yet be certain whether NHYPO is a real diagnostic category.</s><s>Indeed Cusano and colleagues identified 68 subjects with NHYPO, none of whom developed overt hypoparathyroidism on follow-up and persistent disease was noted in 2 of 26 subjects that concluded the follow-up period (4).</s></p><p><s>It is possible that the prevalence of NHYPO by Cusano and colleagues (4) may have underestimated the prevalence in the general population because they only studied men and young women.</s><s>It is important to study older women as many parathyroid diseases such as PHPT have their peak incidence in the first decade after the menopause <ref type="bibr" target="#b9">(10)</ref><ref type="bibr" target="#b10">(11)</ref><ref type="bibr" target="#b11">(12)</ref>.</s></p><p><s>The primary end point of this study is to determine the prevalence and the bone metabolic profile of NHYPO in our population assessing its evolution over the time.</s><s>The secondary endpoint is to evaluate the prevalence of the other calcium metabolic disorders.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Materials and methods</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Study deign and population</head><p><s>We recruited 2419 older women (ages 55-79) and 258 younger women (ages 30-40) from 5</s></p><p><s>European cities (the OPUS study) <ref type="bibr" target="#b12">(13)</ref>.</s><s>To estimate reference intervals for adjusted calcium and PTH, 107 young women were eligible after excluding those with low 25-hydroxyvitamin D (25OHD) (&lt; 20 ng/ml), eGFR &lt; 60 ml/min per 1.73m² , T-score at lumbar spine or total hip equal to or less than -2.5 and those taking drugs or suffering from diseases known to affect bone (Table <ref type="table" target="#tab_4">1</ref>).</s><s>Both adjusted serum calcium and PTH were log10 transformed prior to analysis.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Biochemical measurements</head><p><s>Blood samples were drawn to measure serum:</s></p><p><s>-Calcium and albumin.</s><s>They were measured using the Cobas c701 (Roche Diagnostics, Germany) auto analyser in the Chemical Pathology laboratory, Sheffield Teaching Hospitals, UK.</s><s>The reported inter assay precision is &lt;2.0% for each test.</s><s>We calculated adjusted calcium in all subjects (pre-and post-menopausal women were included in the analysis) based on the total calcium and albumin J at report) we excluded subjects with creatinine &gt; 200 and/or albumin &lt;20 g/L or 50 g/L &gt; and/or total calcium &gt;3 mmol/L.</s><s>In particular, at baseline, 2638 women were included in the analysis and the The inter assay coefficients of variation (CV) were 6.5%, 7.2%, 3.5%, 6.7% and 6.5% respectively.</s></p><p><s>-Creatinine.</s><s>It was measured using the Cobas c 311automated analyser (Roche Diagnostics, Germany).</s><s>This was used to calculate the estimated glomerular filtration rate (eGFR) using the formula based on the modification of diet and renal disease (MDRD) <ref type="bibr" target="#b15">(16)</ref> We measured the samples from baseline and 6 years at the same time.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Bone densitometry</head><p><s>At both visits, bone mineral density (BMD) was performed using dual-energy X-ray absorptiometry (DXA) of the lumbar spine and the proximal femur in posteroanterior projection (Hologic QDR-4500;</s></p><p><s>Hologic, Bedford, MA, USA in the Kiel, Paris, and Sheffield centers) or in anterior-posterior projection (Lunar Expert devices; GE Lunar, Madison, WI, USA in the Aberdeen and Berlin centers).</s></p><p><s>Measurements were standardised and cross calibrated across centres.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Statistical analysis</head><p><s>To classify the abnormalities of calcium homeostasis, we used the following approach:</s></p><p><s>-We calculated adjusted calcium in all subjects based on the total calcium and albumin measurements (see above); -Reference intervals were calculated for adjusted serum calcium and PTH using data from the healthy pre-menopausal women.</s><s>Both adjusted serum calcium and PTH were log10 transformed prior to analysis and the mean +/-1.96SD</s><s>calculated (Table <ref type="table" target="#tab_4">1</ref>).</s></p><p><s>-We allocated older women (baseline) into one of eight categories by using the ellipse defined by the Mahalanobis Distance Analysis (Figure <ref type="figure" target="#fig_2">1</ref>) which measure how far each observation is from the center of a data cluster, taking into account the shape of the cluster.</s><s>Observations are considered We applied the same Mahalanobis Distance Analysis for the older women at follow up (figure <ref type="figure" target="#fig_3">2</ref>).</s><s>In this analysis subjects were included if they had measurements for PTH, calcium and albumin at baseline and follow-up (N = 1416).</s></p><formula xml:id="formula_0">outliers if MD² &gt; 鋼 態 待 苔胎泰 態 = 7.</formula></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Descriptive statistics</head><p><s>Characteristics of the subjects were summarized using frequencies and percentages for categorical variables.</s><s>For continuous variables, mean and standard deviation were calculated.</s><s>Characteristics were compared between groups using ANOVA.</s><s>Post-hoc tests compared all groups to the Normal group using the Dunnett method.</s><s>All measurements with a skewed distribution were log10 transformed prior to analysis and differences between groups were back transformed and expressed as a percentage difference.</s><s>We have performed a multiple regression analyses looking at the relationship between measurements at BMD T-score at baseline; measurements at baseline and change in BMD from baseline 238 to year 6.</s><s>We have examined the change in PTH measurement from baseline to 6 years in the overall population using a paired t-test.</s><s>The -level was set at 0.05.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Subject characteristics</head><p><s>The subject characteristics at baseline are shown in table 2a, table <ref type="table">2b</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Diagnostic categories according to calcium metabolism disorders at baseline</head><p><s>We have identified (Tables <ref type="table" target="#tab_6">3 and 4</ref>):</s></p><p><s>-  <ref type="table">5</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Bone turnover markers (table 4)</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>CTX</head><p><s>We found a statistically significant difference between the normal group and the HH 294 PHPT (difference = 24.0%,</s><s>95% CI: 1.5 to 51.3, p=0.0249), secondary hyperparathyroidism (difference = 28.1%,</s><s>95% CI: 2.8 to 59.5, p=0.020) and non-PTH hypercalcaemia (difference = -54.6%,</s><s>95% CI: -73.2 to -23.3, p=0.001).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Osteocalcin</head><p><s>We found a statistically significant difference between the normal group and secondary hyperparathyroidism (difference = 35.6%,</s><s>95% CI: 18.0 to 55.9, p&lt;0.001).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Bone ALP</head><p><s>We found a statistically significant difference between the normal group and non-PTH hypercalcaemia group (difference = -27.2%,</s><s>95% CI: -45.80 to -2.3, p=0.023).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>PINP</head><p><s>There were no statistically significant differences when we compared the normal group to the other different categories.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Stability of PTH over time</head><p><s>In the overall population there is a statistically significant change in PTH measurement from baseline.</s><s>The mean PTH measurement increased from 41.6 (SD = 21.1) at baseline to 45.5 (SD = 26.1) at six years (mean change = 3.9, 95% CI: 2.79 to 4.98, P&lt;0.001).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Discussion</head><p><s>This is the first study that has investigated the prevalence of NHYPO in a large cohort of postmenopausal women.</s><s>Once again these findings confirm the key role of PTH in the bone metabolism: a few studies have demonstrated that daily subcutaneous injections of PTH (1-84) result in a significant increase of bone formation and resorption markers (that were suppressed at baseline) in patients affected by hypoparathyroidism <ref type="bibr" target="#b21">(22)</ref>.</s></p><p><s>Our data on NHYPO raise questions on the appropriate management of thi P wait We don't have sufficient data for recommendations for these 345 subjects.</s><s>Anyway if the patients take a medication that might induce hypocalcemia, such as an anti-resorptive drug (such as bisphosphonate, denosumab) or a loop-acting diuretic (such as furosemide) then monitoring of serum calcium is to be recommended.</s><s>Therefore the potential choice of the treatment for subjects with NHYPO affected by osteoporosis is critical.</s><s>Indeed powerful anti-resorptive drugs such as bisphosphonates and denosumab, could exacerbate the risk of adynamic bone disease by suppressing the bone turnover <ref type="bibr" target="#b22">(23)</ref>.</s><s>Conversely, anabolic therapy could restore the physiological bone turnover (24) but we are not able to predict if patients with NHYPO will experience an improvement in BMD.</s><s>Indeed, in contrast to the effect of PTH (1 84) treatment in patients with osteoporosis, PTH (1-84) replacement therapy causes a general decrease in BMD at the hip, lumbar spine and whole body (apart from the forearm) in subjects with hypoparathyroidism <ref type="bibr" target="#b21">(22)</ref>.</s><s>Despite the significant changes in bone turnover, teriparatide did not provide any significant BMD improvement in hypoparathyroidism <ref type="bibr" target="#b19">(20)</ref>.</s><s>In particular, after 3 years of twice daily PTH <ref type="bibr">(1 34)</ref> treatment, BMD and bone mineral content (BMC) at the lumbar spine, femoral neck, and whole body maintained stable although there was a non-significant downward trend in the distal one-third radius BMD.</s></p><p><s>It was noteworthy that the prevalence of PHPT was so high.</s><s>The biochemical abnormality of high serum calcium and high or high-normal PTH is also found in familial hypocalciuric hypercalcemia but we did not conduct any calcium excretion studies or gene testing to role out it.</s><s>Most our cases were mild and the mean PTH was only at the upper limit of the reference interval for PTH; this might explain why most bone turnover markers were normal.</s><s>The diagnosis of hypercalcaemia was made on samples after the second visit so it did not influence clinical management during the follow-up period.</s></p><p><s>It was also surprising that our rate of NPHPT was lower than in the MrOS as many epidemiological studies have confirmed that hyperparathyroidism is less frequent in men <ref type="bibr" target="#b24">(25,</ref><ref type="bibr" target="#b25">26)</ref>.</s><s>Other large retrospective studies have attempted to evaluate the epidemiology of NPHPT but most have not ruled out the main causes of secondary hyperparathyroidism <ref type="bibr" target="#b26">(27)</ref><ref type="bibr" target="#b27">(28)</ref><ref type="bibr" target="#b29">(29)</ref>.</s><s>Probably the low prevalence of NPHPT in our population may be explained by the high rate of vitamin D insufficiency (52.3%, data not shown) and eGFR reduction (62.4 %, data not shown); the former due to geographical differences and that latter due to the higher mean age in c C</s></p><p><s>Probably the current definition of NPHPT tends to underestimate the prevalence of this category.</s></p><p><s>Indeed according the data published by Shibli-Rahhal <ref type="bibr" target="#b30">(30)</ref>, in our population only 10.7% (data not shown) of older women with 25OHD &lt; 20 ng/ml had an elevated PTH.</s></p><p><s>However, circulating PTH concentrations display a large inter-individual variability: calcium intake, some drugs such as lithium, MgSO4, diuretics etc. are able to affect the PTH serum levels.</s><s>Moreover that there is about a 1% increase in intact PTH every year in women, with an faster rise after the menopause <ref type="bibr" target="#b36">(36,</ref><ref type="bibr" target="#b37">37)</ref>; therefore the 9% increase we observed is likely to be age-related rather than resulting from minor degradation.</s><s>Moreover if the low prevalence of SHPT and relatively high prevalence of NHYPO had been attributable to degradation of PTH during storage, we would have expected also a low prevalence of hyperparathyroid hypercalcemia (PHPT and FHH).</s><s>Instead we have a high prevalence of hyperparathyroid hypercalcemia.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>I C "HPT</head><p><s>low.</s><s>This could be explained by the higher dietary calcium intake found in European countries compared to the US population.</s><s>In one review, the mean calcium intake in the NHANES III study in older women 402 was 600 mg/day, considerable lower than the estimates for UK (800 mg), France (850 mg) and Germany (970 mg) <ref type="bibr" target="#b38">(38)</ref>.</s><s>This is the first large population based study that has investigated the prevalence and the bone metabolic status of NPHPT in postmenopausal women: it is fairly common, not always persistent and is characterized by low bone turnover.</s><s>The pink rectangle identifies subjects with normocalcemic hypoparathyroidism.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head></head><label></label><figDesc><div><p><s>local adjustment equation was expressed by the following relationship: adjusted Calcium = Total Calcium -(0.015 x albumin) + 0.699.</s><s>After six years follow up (1652 women were included in the analysis), the local adjustment equation was expressed by the following relationship: adjusted Calcium = Total Calcium -(0.018 x albumin) + 1.581 -Collagen type 1 cross-linked C-telopeptide (CTX), intact procollagen type 1 N propeptide (PINP), bone alkaline phosphatase (bone ALP), 25OHD and PTHi.</s><s>They were measured in serum using the IDS-iSYS automated immunoassays (Immunodiagnostic Systems, Boldon, United Kingdom).</s><s>185</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head></head><label></label><figDesc><div><p><s>this variance has been demonstrated to have a strong hereditable component<ref type="bibr" target="#b0">(1)</ref> but the genetic factors governing serum PTH concentrations remain unknown.</s><s>Indeed, although it is well documented that loss of function and gain of function mutations of the CaSR lead respectively to hypercalcemic and hypocalcemic disorders<ref type="bibr" target="#b31">(31)</ref>, no studies aimed to assess the status of CaSR in NPHPT and hypoparathyroidism subjects.</s><s>Another interesting area of research could be the evaluation of the autoantibodies directed against the extracellular domain of the CaSR and NALP5 in subjects with NHYPO.</s><s>Previous studies have identified the CaSR and NALP5 as parathyroid autoantibody targets in patients with autoimmune polyendocrinopathy-candidiasis ectodermal dystrophy<ref type="bibr" target="#b32">(32)</ref> or in subjects with autoimmune hypocalciuric hypercalcemia<ref type="bibr" target="#b33">(33)</ref><ref type="bibr" target="#b34">(34)</ref><ref type="bibr" target="#b35">(35)</ref> but it is unclear whether these antibodies may also contribute to the variability in serum PTH concentrations observed in normocalcaemic individuals.OW cium and f have any biochemical data between the first visit at baseline and the second visit at 6 years later, we have only a single value for each laboratory analyte at each time point, we lost a significant number of subjects over the course of the study and BMD analysis was performed by two different instruments.</s><s>Moreover the prevalence of the different diagnostic categories might be affected by long-term PTH storage.</s><s>Anyway we do not think that relatively high prevalence of NHYPO could be attributable to degradation of PTH during storage.</s><s>Indeed it has been estimated by some authors</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>Figure 1 .</head><label>1</label><figDesc><div><p><s>Figure 1.</s><s>Baseline data results for adjusted calcium and PTH.</s><s>The ellipse was derived using Mahalanobis distances method to define normal (black) and abnormal (red) values.</s><s>The horizontal and vertical lines indicate the geometric mean, and reference intervals described inTable 1.</s><s>The pink rectangle identifies subjects with normocalcemic hypoparathyroidism.</s></p></div></figDesc><graphic coords="20,72.00,172.70,451.29,373.75" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_3"><head>Figure 2 .</head><label>2</label><figDesc><div><p><s>Figure 2. Follow-up results for adjusted calcium and PTH.</s><s>The ellipse was derived using Mahalanobis distances method to define normal (black) and abnormal (red) values.</s><s>The horizontal and vertical lines indicate the geometric mean, and reference intervals obtained from the healthy young women.</s></p></div></figDesc><graphic coords="21,72.00,172.72,394.29,376.30" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head></head><label></label><figDesc><div><p><s>At baseline, no statistically significant differences have been found between the different groups compared to the normal subjects with regards to age, BMI and lumbar spine BMD.</s><s>According to its</s></p></div></figDesc><table><row><cell>-1 subject (0.1%) affected by NPHPT. At the second visit no subjects met the diagnostic criteria for Bone metabolic parameters</cell></row><row><cell>the normocalcemic hyperparathyroidism. BMD</cell></row><row><cell>At baseline, no statistically significant differences have been found between the different groups</cell></row><row><cell>-69 subjects (2.8%) subjects affected by secondary hyperparathyroidism: low calcium (2.16 mmol/L, compared to normal subjects at the lumbar spine. Post-hoc testing has been demonstrated a</cell></row><row><cell>95% CI 2.09 2.23) with high or high normal PTH (88.9 ng/L, 95% CI 75.8 104.3). statistically significant difference in the mean hip T-Score between the normal group and the</cell></row><row><cell>secondary hyperparathyroidism group (difference = -0.47, 95% CI: -0.83 to -0.11, p=0.004). The</cell></row><row><cell>-3 subjects (0.1%) affected by hypoparathyroidism; lumbar spine and hip BMD change over the time (rate of bone loss per year from the baseline) did</cell></row><row><cell>not show any statistically significant differences between abnormal calcaemia categories compared</cell></row><row><cell>-57 subjects (2.4%) affected by NHYPO: normal calcium (2.39 mmol/L, 95% CI 2.36 2.42) with low to the normal group. The baseline total hip BMD is inversely related to serum PTH (R= -0.006,</cell></row><row><cell>PTH (10.1 ng/L, 95% CI 9.2 11.1). p&lt;0.001), age (R= -0.058, p&lt;0.001). It is also positively related to BMI (R= 0.105, p&lt;0.001). The</cell></row><row><cell>change in total hip BMD is inversely related to serum calcium (R= -27.567, p&lt;0.001) and age (R= -</cell></row><row><cell>-12 subjects (0.5%) affected by non-PTH hypercalcaemia: high calcium (2.82 mmol/259 L, 95% CI 0.425, p=0.029) (Table</cell></row><row><cell>2.75 2.89) with low or low normal PTH (18.5 ng/L, 95% CI 16.2 21.3).</cell></row><row><cell>definition, secondary hyperparathyroidism has been shown a statistically significant difference in</cell></row><row><cell>2063 subjects (85.3%) with no calcium abnormalities: normal adjusted calcium levels (2.4 mmol/L, terms of 25 (OH) vitamin D and eGFR compared to the normal group (respectively, difference = -</cell></row><row><cell>95% CI 2.39 -2.41) with normal PTH (39 ng/L, 95% CI 38.4 39.7); 15.9%, 95% CI: -27.2 to -2.8, p=0.011. Difference = -16.0%, 95% CI: -21.8 to -9.8, p&lt;0.001). In subjects</cell></row><row><cell>with HH and non-PTH hypercalcaemia there is a statistically significant reduction in terms of eGFR</cell></row><row><cell>-86 subjects (3.6%) affected by HH: high calcium levels (2.79 mmol/L, 95% CI 2.78 2.80) with compared to the normal group (respectively, difference = -11.7%, 95% CI: -17.4 to -5.7, p&lt;0.001;</cell></row><row><cell>elevated PTH (58.80 ng/L, 95% CI 52.6 65.8). At the second visit (after 6 years), of the 56 HH Difference = -17.0%, 95% CI: -30.3 to -1.2, p=0.024).</cell></row><row><cell>subjects with follow-up data, 47 (2%) subjects had persistent evidence of HH.</cell></row></table><note><p><s>Normocalcemic hypoparathyroidismThere are statistically significant differences if we compare the NHYPO group with the normal group in 264 terms of BAP (difference = -15.4%,95%CI:-26.2 to -3.0, p=0.007),CTX (difference = -66.3%,95%CI:-74.0 to -56.4,p&lt;0.001)andosteocalcin</s><s>(difference = -36.8%,95%CI:-45.6 to -26.6, p&lt;0.001).Baseline BMD parameters and the lumbar spine and hip change over the time have not been shown any statistically significant differences compared to the normal group.At the second visit (after 6 years), of the 35 NHYPO subjects with follow-up data, none developed overt hypoparathyroidism and only 15 (0.6%) subjects had persistent evidence of NHYPO.Comparisons between the different categories and normal subjects (Tables3,4)</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_3"><head></head><label></label><figDesc><div><p><s>Cusano et al have previously conducted a large trial to evaluate the epidemiology of these subclinical conditions in an unselected community-based sample of old men (The Osteoporotic Fractures in Men study, MrOS study) and young men with premenopausal women</s></p></div></figDesc><table><row><cell cols="3">(Dallas Heart Study, DHS) revealing a prevalence respectively of 0.4% and 3.1% for NPHPT and of</cell></row><row><cell cols="3">1.1% and 1.9% respectively for NHYPO (4). At baseline we identified 57 subjects (2.4%) affected by</cell></row><row><cell cols="3">NHYPO and just 1 subject (0.1%) affected by normal hyperparathyroidism after ruling out the main</cell></row><row><cell cols="3">causes of secondary hyperparathyroidism (vitamin D deficiency, eGFR &lt; 60 ml/min and only 6</cell></row><row><cell cols="3">A few studies have shown that bone turnover marker levels are frankly low or low-normal in patients</cell></row><row><cell cols="3">with hypoparathyroidism compared to normal subjects (17-20) and these findings are consistent</cell></row><row><cell cols="3">with histomorphometric analysis. In particular double-tetracycline labelling of bone biopsy</cell></row><row><cell cols="3">specimens have demonstrated that dynamic skeletal indices are suppressed in hypoparathyroid</cell></row><row><cell cols="2">patients (21). According to</cell><cell>NHYPO</cell></row><row><cell>turn</cell><cell cols="2">cant BMD change over the time compared to the normal group. Indeed,</cell></row></table><note><p><s>NHYPO subjects were taking proton pump inhibitors).In our cohort the prevalence of NHYPO is higher in comparison with the previous study: this is probably due to the differences in gender and age between the three populations.Even if the baseline cross-sectional data indicate the existence of the NHYPO as a new subclinical pathological category, the longitudinal data give rise to many doubts.Indeed at the 6 years visit, of the 35 NHYPO subjects with follow-up data, none of them developed overt hypoparathyroidism and only 15 (0.6%) out of 35 subjects had persistent evidence of NHYPO.This finding is in keeping with that reported by others; Cusano and colleagues identified 68 subjects with NHYPO, none of whom developed overt hypoparathyroidism on follow-up and persistent disease was noted in 2 of 26 subjects with follow-up (4).we</s><s>found a significant reduction in serum levels of CTX, BAP and osteocalcin compared to subjects with no impairment of calcium metabolism.</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_4"><head>Table 1 .</head><label>1</label><figDesc><div><p><s>Reference Intervals for Adjusted Calcium and PTH Healthy Young Women.</s></p></div></figDesc><table><row><cell></cell><cell>Geometric</cell><cell>Reference</cell><cell>95% CI of lower</cell><cell>95% CI of upper</cell><cell>Mean (SD)</cell></row><row><cell></cell><cell>Mean</cell><cell>Range</cell><cell>limit of</cell><cell>limit of reference</cell><cell>log 10</cell></row><row><cell></cell><cell></cell><cell></cell><cell>reference range</cell><cell>range</cell><cell></cell></row><row><cell>Adjusted Serum</cell><cell>2.359</cell><cell>2.123 2.620</cell><cell>2.086 2.160</cell><cell>2.575 2.667</cell><cell>0.373</cell></row><row><cell>Calcium</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>(0.023)</cell></row><row><cell>(mmol/L)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>(N = 107)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>PTH</cell><cell>25.707</cell><cell>10.937 60.419</cell><cell>9.493 12.602</cell><cell>52.441 69.612</cell><cell>1.410</cell></row><row><cell>(ng/L)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>(0.189)</cell></row><row><cell>(N=107)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_5"><head>Table 2a .</head><label>2a</label><figDesc><div><p><s>Baseline characteristics of the older and younger women in the OPUS study (ng/mL) 440 25.4 12.6 2311 21.3 10.3 eGFR (mL/minute/1.73m²)</s><s>439 86.1 12.3 2317 57.5 13.5 Calcium (mmol/L) 440 2.37 0.13 2320 2.39 0.16 Table 2b.</s><s>Baseline characteristics for normal and NHYPO subjects</s></p></div></figDesc><table><row><cell>Premenopausal N Mean SD 463 31.3 5.5 2419 67.1 Postmenopausal N Mean SD 7.1 463 166.0 6.7 2418 160.3 6.3 463 66.3 13.0 2418 68.7 12.3 463 24.0 4.4 2418 26.7 4.5 Lumbar Spine BMD T-Score 462 0.09 1.12 2372 -0.94 1.51 Age (years) Height (cm) Weight (kg) BMI (kg/m²) Total Hip BMD T-Score 462 0.27 1.01 2396 -0.64 1.16 CTX (ng/mL) 423 0.25 0.17 2287 0.36 0.27 PINP (ng/mL) 435 39.7 20.6 2260 42.5 22.0 Bone ALP (ng/mL) 441 11.5 5.1 2313 15.1 6.4 Osteocalcin (ng/mL) 441 21.2 8.0 2303 24.5 13.9 (years) BMI (Kg/m²) Spine T-Score N Mean (95% CI) N Mean (95% CI) N Mean (95% CI) Normal 2063 67.0 (66.7, 67.3) 2062 26.6 (26.5, 26.8) 2024 -0.95 (-1.01, -0.88) Normocalcaemic Hypoparathyroidism 57 66.3 (64.6, 67.9) 57 26.2 (25.1, 27.3) 57 -0.64 (-1.07, 0.21) 25 (OH) Vitamin D Age P-Value a ns ns ns</cell><cell>N 2043 57</cell><cell>Hip T-Score Mean (95% CI) -0.64 (-0.69, 0.59) -0.47 (-0.78, -0.16) ns</cell></row></table><note><p><s>a P-Value from ANOVA testing for an overall difference in means</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_6"><head>Table 3 .</head><label>3</label><figDesc><div><p><s>Baseline calcium metabolism characteristics for each category.</s><s>P-Value from ANOVA testing for an overall difference in means Post-hoc testing for a difference in mean from the Normal group: * P-Value &lt;0.050, ** P-Value &lt; 0.010, *** P-Value &lt; 0.001</s></p></div></figDesc><table><row><cell></cell><cell cols="2">Adjusted Calcium</cell><cell></cell><cell>PTH</cell><cell></cell><cell>25(OH)D</cell><cell></cell><cell>eGFR</cell></row><row><cell></cell><cell cols="2">(mmol/L)</cell><cell></cell><cell>(ng/L)</cell><cell></cell><cell>(ng/ml)</cell><cell></cell><cell>(ml/min)</cell></row><row><cell></cell><cell>N</cell><cell>Geometric</cell><cell>N</cell><cell>Geometric</cell><cell>N</cell><cell>Geometric</cell><cell>N</cell><cell>Geometric</cell></row><row><cell></cell><cell></cell><cell>Mean</cell><cell></cell><cell>Mean</cell><cell></cell><cell>Mean</cell><cell></cell><cell>Mean</cell></row><row><cell></cell><cell></cell><cell>(95% CI)</cell><cell></cell><cell>(95% CI)</cell><cell></cell><cell>(95% CI)</cell><cell></cell><cell>(95% CI)</cell></row><row><cell>Normal</cell><cell>2063</cell><cell>2.40</cell><cell>2063</cell><cell>39.0</cell><cell>2058</cell><cell>19.2</cell><cell>2060</cell><cell>56.7</cell></row><row><cell></cell><cell></cell><cell>(2.39, 2.41)</cell><cell></cell><cell>(38.4, 39.7)</cell><cell></cell><cell>(18.9, 19.6)</cell><cell></cell><cell>(56.1, 57.2)</cell></row><row><cell>Primary</cell><cell>86</cell><cell>2.79***</cell><cell>86</cell><cell>58.8***</cell><cell>85</cell><cell>17.9</cell><cell>85</cell><cell>50.0***</cell></row><row><cell>Hyperparathyroidism</cell><cell></cell><cell>(2.78, 2.80)</cell><cell></cell><cell>(52.6, 65.8)</cell><cell></cell><cell>(16.1, 19.9)</cell><cell></cell><cell>(47.8, 52.2)</cell></row><row><cell>Secondary</cell><cell>69</cell><cell>2.16***</cell><cell>69</cell><cell>88.9***</cell><cell>69</cell><cell>16.2*</cell><cell>69</cell><cell>47.6***</cell></row><row><cell>Hyperparathyroidism</cell><cell></cell><cell>(2.09, 2.23)</cell><cell></cell><cell>(75.8, 104.3)</cell><cell></cell><cell>(14.1, 18.6)</cell><cell></cell><cell>(44.1, 51.3)</cell></row><row><cell>Normocalcaemic</cell><cell>57</cell><cell>2.39</cell><cell>57</cell><cell>10.1***</cell><cell>57</cell><cell>20.7</cell><cell>57</cell><cell>53.0</cell></row><row><cell>Hypoparathyroidism</cell><cell></cell><cell>(2.36, 2.42)</cell><cell></cell><cell>(9.2, 11.1)</cell><cell></cell><cell>(18.0, 23.8)</cell><cell></cell><cell>(50.3, 55.9)</cell></row><row><cell>Non-PTH</cell><cell>12</cell><cell>2.82***</cell><cell>12</cell><cell>18.6***</cell><cell>12</cell><cell>19.9</cell><cell>12</cell><cell>47.0*</cell></row><row><cell>Hypercalcaemia</cell><cell></cell><cell>(2.75, 2.89)</cell><cell></cell><cell>(16.2, 21.3)</cell><cell></cell><cell>(15.1, 26.2)</cell><cell></cell><cell>(40.8, 54.2)</cell></row><row><cell>P-Value a</cell><cell></cell><cell>&lt;0.001</cell><cell></cell><cell>&lt;0.001</cell><cell></cell><cell>0.015</cell><cell></cell><cell>&lt;0.001</cell></row></table><note><p><s>a</s></p></note></figure>
		</body>
		<back>
			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0" />			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Genetic contribution to bone metabolism, calcium excretion, and vitamin D and parathyroid hormone regulation</title>
		<author>
			<persName><forename type="first">D</forename><surname>Hunter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">De</forename><surname>Lange</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Snieder</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Bone Miner Res</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page" from="371" to="378" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Identification of 70 calcium-sensing receptor mutations in hyper-and hypo-calcaemic patients: evidence for clustering of extracellular domain mutations at calcium-binding sites</title>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">M</forename><surname>Hannan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Cranston</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Hum Mol Genet</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page" from="2768" to="2778" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Genome-wide meta-analysis for serum calcium identifies significantly associated SNPs near the calcium-sensing receptor (CASR) gene</title>
		<author>
			<persName><forename type="first">K</forename><surname>Kapur</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Johnson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">D</forename><surname>Beckmann</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">PLoS genetics</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page">e1001035</biblScope>
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Normocalcemic hyperparathyroidism and hypoparathyroidism in two community-based nonreferral populations</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">E</forename><surname>Cusano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">M</forename><surname>Maalouf</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">Y</forename><surname>Wang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Endocrinol Metab</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page" from="2734" to="2741" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Diagnosis of asyntomatic primary hyperparathyroidism:proceedings of the fourth international workshop</title>
		<author>
			<persName><forename type="first">R</forename><surname>Eastell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">L</forename><surname>Brandi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">G</forename><surname>Costa</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Endocrinol Metab</title>
		<imprint>
			<biblScope unit="volume">99</biblScope>
			<biblScope unit="page" from="3570" to="3579" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international workshop</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Bilezikian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">A</forename><surname>Khan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Potts</forename><surname>Jr</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">T</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Journal of Clinical Endocrinology &amp; Metabolism</title>
		<imprint>
			<biblScope unit="volume">94</biblScope>
			<biblScope unit="page" from="335" to="339" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Normocalcemic hyperparathyroidism in patients with osteoporosis</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Monchik</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Gorgun</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Surgery</title>
		<imprint>
			<biblScope unit="volume">136</biblScope>
			<biblScope unit="page" from="1242" to="1246" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">The surgical managment of asyntomatic primary hyperparathyroidism: proceedings of the fourth international workshop</title>
		<author>
			<persName><forename type="first">R</forename><surname>Udelsman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Akerstorm</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Biagini</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Endocrinol Metab</title>
		<imprint>
			<biblScope unit="volume">99</biblScope>
			<biblScope unit="page" from="3595" to="3606" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Hypocalcemia associated with alendronate</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">H</forename><surname>Schussheim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">P</forename><surname>Jacobs</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Silverberg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Annals of internal medicine</title>
		<imprint>
			<biblScope unit="volume">130</biblScope>
			<biblScope unit="page" from="329" to="329" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Silverberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Shane</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">P</forename><surname>Jacobs</surname></persName>
		</author>
		<idno>341:1249 1255</idno>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Normocalcemic Primary Hyperparathyroidism</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">E</forename><surname>Cusano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Silverberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Bilezikian</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Densitom</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page">39</biblScope>
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Primary hyperparathyroidism across the ages: presentation and outcomes</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">C</forename><surname>Oltmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">H</forename><surname>Rajaei</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">S</forename><surname>Sippel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">F</forename><surname>Schneider</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Surg Res</title>
		<imprint>
			<biblScope unit="volume">190</biblScope>
			<biblScope unit="page" from="185" to="190" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Association of Five Quantitative Ultrasound Devices and Bone Densitometry With Osteoporotic Vertebral Fractures in a Population-Based Sample: The OPUS Study</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">C</forename><surname>Glüer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Eastell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Reid</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Bone Miner Res</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="page" from="782" to="793" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Reproducibility of a questionnaire on risk factors for osteoporosis in a multicentre prevalence survey: the European Vertebral Osteoporosis Study</title>
		<author>
			<persName><forename type="first">T</forename><surname>O'neill</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Cooper</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Cannata</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">International journal of epidemiology</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page" from="559" to="565" />
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Derivation and internal validation of an equation for albumin-adjusted calcium</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">T</forename><surname>James</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">W</forename><surname>Lyon</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">BMC clinical pathology</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="page" from="8" to="12" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Expressing the modification of diet in renal disease study equation for estimating glomerular filtration rate with standardized serum creatinine values</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">S</forename><surname>Levey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Coresh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Greene</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clinical Chemistry</title>
		<imprint>
			<biblScope unit="volume">53</biblScope>
			<biblScope unit="page" from="766" to="772" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Clinical Validation of a New Immunoradiometric Assay for Intact Human Osteocalcin</title>
		<author>
			<persName><forename type="first">S</forename><surname>Minisola</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">T</forename><surname>Pacitti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Romagnoli</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Calcif Tissue Int</title>
		<imprint>
			<biblScope unit="volume">64</biblScope>
			<biblScope unit="page">369</biblScope>
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Clinical Evaluation of the Elecsys b-CrossLaps Serum Assay, a New Assay for Degradation Products of Type I Collagen C-Telopeptides</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">N</forename><surname>Okabe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Inaba</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Miki</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clinical Chemistry</title>
		<imprint>
			<biblScope unit="volume">47</biblScope>
			<biblScope unit="page" from="1410" to="1414" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Circulating Sclerostin in Disorders of Parathyroid Gland Function</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">G</forename><surname>Costa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Cremens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">R</forename><surname>Rubin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Endocrinol Metab</title>
		<imprint>
			<biblScope unit="volume">96</biblScope>
			<biblScope unit="page">3810</biblScope>
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Mini-review: new therapeutic options in hypoparathyroidism</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">E</forename><surname>Cusano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">R</forename><surname>Rubin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Sliney</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Endocrine</title>
		<imprint>
			<biblScope unit="volume">41</biblScope>
			<biblScope unit="page" from="410" to="414" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Dynamic and structural properties of the skeleton in hypoparathyroidism</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">R</forename><surname>Rubin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">W</forename><surname>Dempster</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Zhou</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Bone Miner Res</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page" from="2018" to="2024" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">The Effect of Adding PTH(1 84) to Conventional Treatment of Hypoparathyroidism: A Randomized, Placebo-Controlled Study</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">R</forename><surname>Sikjaer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Rolighed</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Hickendorff</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Bone Miner Res</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page">2370</biblScope>
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Adynamic bone disease: clinical and therapeutic implications</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Frazao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Martins</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Curr Opin Nephrol Hypertens</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="page" from="303" to="307" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Synthetic human parathyroid hormone 1-34 replacement therapy: a randomized crossover trial comparing pump versus injections in the treatment of chronic hypoparathyroidism</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">K</forename><surname>Winer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Shrader</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Endocrinol Metab</title>
		<imprint>
			<biblScope unit="volume">97</biblScope>
			<biblScope unit="page" from="391" to="399" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Characterization of normocalcemic primary hyperparathyroidism</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">M</forename><surname>Tordjman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Greenman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Osher</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Med</title>
		<imprint>
			<biblScope unit="volume">117</biblScope>
			<biblScope unit="page" from="861" to="863" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Normocalcemic primary hyperparathyroidism: further characterization of a new clinical phenotype</title>
		<author>
			<persName><forename type="first">H</forename><surname>Lowe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Mcmahon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">R</forename><surname>Rubin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Endocrinol Metab</title>
		<imprint>
			<biblScope unit="volume">92</biblScope>
			<biblScope unit="page">3005</biblScope>
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Population-based screening 474 for primary hyperparathyroidism with serum calcium and parathyroid hormone values in menopausal women</title>
		<author>
			<persName><forename type="first">E</forename><surname>Lundgren</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Rastad</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Thrufjell</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Surgery</title>
		<imprint>
			<biblScope unit="volume">121</biblScope>
			<biblScope unit="page" from="287" to="294" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<monogr>
		<title level="m" type="main">New data on the impact of renal function on the relationship between 25-hydroxyvitamin D and Parathyroid Hormone</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">M</forename><surname>Misra</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Silverberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Bilezikian</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2008">2008</date>
		</imprint>
		<respStmt>
			<orgName>Annual Meeting of the American Society of Bone and Mineral Research</orgName>
		</respStmt>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">Canada</forename><surname>Montreal</surname></persName>
		</author>
		<imprint>
			<date type="published" when="1031">1031</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<monogr>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">L</forename><surname>Berger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Hanley</surname></persName>
		</author>
		<title level="m">Prevalence of Normocalcemic and Hypercalcemic Hyperparathryoidism in a Community-Dwelling Cohort. Program of the 33rd Annual Meeting of the American Society of Bone and Mineral Research</title>
				<imprint>
			<date type="published" when="2011">2011</date>
			<biblScope unit="page">U0173</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Variations in parathyroid hormone concentration in patients with low 25 hydroxyvitamin D</title>
		<author>
			<persName><forename type="first">A</forename><surname>Shibli-Rahhal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Paturi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Osteoporos Int</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="page">1936</biblScope>
			<date type="published" when="1931">2014. 1931</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">Calcium-sensing receptor (CaSR) mutations and disorders of calcium, electrolyte and water metabolism</title>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">M</forename><surname>Hannan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">V</forename><surname>Thakker</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Best Pract Res Clin Endocrinol Metab</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="page" from="359" to="371" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">Prevalence and Clinical Associations of Calcium-Sensing Receptor and NALP5 Autoantibodies in Finnish APECED Patients</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">H</forename><surname>Kemp</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Habibullah</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Kluger</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Endocrinol Metab</title>
		<imprint>
			<biblScope unit="volume">99</biblScope>
			<biblScope unit="page" from="1064" to="1071" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">Acquired hypocalciuric hypercalcemia due to autoantibodies against the calcium-sensing receptor</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Pallais</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Kifor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">B</forename><surname>Chen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">351</biblScope>
			<biblScope unit="page">369</biblScope>
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">Autoimmune hypocalciuric hypercalcemia 493 unresponsive to glucocorticoid therapy in a patient with blocking autoantibodies against the calcium sensing receptor</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Pallais</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">H</forename><surname>Kemp</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Bergwitz</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Endocrinol Metab</title>
		<imprint>
			<biblScope unit="volume">96</biblScope>
			<biblScope unit="page" from="672" to="680" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">A syndrome of hypocalciuric hypercalcemia caused by autoantibodies directed at the calcium-sensing receptor</title>
		<author>
			<persName><forename type="first">O</forename><surname>Kifor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">D</forename><surname>Moore</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Delaney</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Endocrinol Metab</title>
		<imprint>
			<biblScope unit="volume">88</biblScope>
			<biblScope unit="page" from="60" to="72" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">A unitary model for involutional osteoporosis: estrogen deficiency causes both type I and type II osteoporosis in postmenopausal women and contributes to bone loss in aging men</title>
		<author>
			<persName><forename type="first">Bl1</forename><surname>Riggs</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Khosla</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">J</forename><surname>Melton</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Bone Miner Res</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="763" to="773" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">Effects of age and estrogen status on serum parathyroid hormone levels and biochemical markers of bone turnover in women: a populationbased study</title>
		<author>
			<persName><forename type="first">S</forename><surname>Khosla</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">J</forename><surname>Atkinson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">J</forename><surname>Melton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">L</forename><surname>Riggs</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Endocrinol Metab</title>
		<imprint>
			<biblScope unit="volume">82</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="1522" to="1527" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">Dietary calcium: recommendations and intakes around the world</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">C</forename><surname>Looker</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">Calcium in Human Health</title>
				<editor>
			<persName><forename type="first">C</forename><surname>Weaver</surname></persName>
		</editor>
		<editor>
			<persName><forename type="first">R</forename><forename type="middle">P</forename><surname>Heaney</surname></persName>
		</editor>
		<imprint>
			<publisher>Humana Press Inc</publisher>
			<date type="published" when="2006">2006</date>
			<biblScope unit="page" from="105" to="128" />
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
